CAJ | 학술논문

目的探讨乳腺癌肺转移患者的临床病理特点及预后因素.方法回顾性分析2000年1月至2007年1月天津医科大学附属肿瘤医院收治的1 19例乳腺癌肺转移患者的临床及随访资料.结果 119例乳腺癌肺转移患者中,激素受体(hormone receptor,HR)+/人表皮生长因子受体(human epithelial growth factor receptor,HER2)-、HR +/HER2+、HR-/HER2+和三阴性乳腺癌(triple negative breast cancer,TNBC)各亚型所占比例分别为35.3％、17.6％、21.8％、25.2％,其中三阴性乳腺癌与其他亚型相比组织学分级Ⅲ级发生率较高(P=0.016).本组患者的中位生存期为60个月(9 ～ 141个月),中位肺转移时间为29个月(3～ 99个月),发生肺转移后的中位生存期是33个月(6 ～98个月),1、2、3、5年生存率分别是72.9％、54.1％、35.1％和14.4％.结论三阴性乳腺癌、多发肺转移灶、肺转移时间≤24个月及是否曾接受系统化疗是影响肺转移患者预后的独立危险因素.
목적 탐토유선암폐전이환자적림상병리특점급예후인소.방법 회고성분석2000년1월지2007년1월천진의과대학부속종류의원수치적1 19례유선암폐전이환자적림상급수방자료.결과 119례유선암폐전이환자중,격소수체(hormone receptor,HR)+/인표피생장인자수체(human epithelial growth factor receptor,HER2)-、HR +/HER2+、HR-/HER2+화삼음성유선암(triple negative breast cancer,TNBC)각아형소점비례분별위35.3％、17.6％、21.8％、25.2％,기중삼음성유선암여기타아형상비조직학분급Ⅲ급발생솔교고(P=0.016).본조환자적중위생존기위60개월(9 ～ 141개월),중위폐전이시간위29개월(3～ 99개월),발생폐전이후적중위생존기시33개월(6 ～98개월),1、2、3、5년생존솔분별시72.9％、54.1％、35.1％화14.4％.결론 삼음성유선암、다발폐전이조、폐전이시간≤24개월급시부증접수계통화료시영향폐전이환자예후적독립위험인소.
Objective To investigate the clinicopathological characteristics and prognosis of lung metastases from breast cancer.Methods The clinical data of 119 breast cancer patients treated at our institution from January 2000 to January 2007 were retrospectively reviewed.Results Among 119 patients with lung metastasis,35.3％ was hormone receptor (HR) +/human epithelial growth factor receptor (HER2)-,17.6％ was HR +/HER2 +,21.8％ was HR-/HER2 + and 25.2％ was trriple negative breast cancer (TNBC).The rate of grade Ⅲ in triple negative breast cancer was higher than the other subtypes(P =0.016).The median overall survival was 60 months (9-141 months),the median time to lung metastases was 29 months (3-99 months),and the median survival after lung metastasis was 33 months (range,6-98 months).The 1-,2-,3-and 5-year survival rate was 72.9％,54.1％,35.1％ and 14.4％.Conclusions TNBC,number of lung metastases,time to lung metastases less than 24 months,and a history of systemic chemotherapy were important factors for prognosis of patients with lung metastases.